BioMed X, an innovation engine for the pharmaceutical sector, and Boehringer Ingelheim have announced the launch of a new research team within XSeed Labs, the innovation incubator based at Boehringer’s US research and development headquarters in Ridgefield, Connecticut. The initiative extends an existing collaboration between the two organisations and adds a further research strand focused […]
Estonia-based biotechnology company Icosagen has completed a €45 million expansion programme designed to bring therapeutic protein discovery, development and Good Manufacturing Practice (GMP) production together at a single site in Tartu, Estonia. The initiative establishes what the company describes as a continuous pathway from early-stage discovery through to clinical manufacturing of complex protein therapeutics.
Abcam and EpiCypher have announced a partnership intended to improve the reliability of antibodies used in ChIC/CUT&RUN epigenomic profiling, a development that clinical laboratory scientists working in chromatin biology and biomarker research may wish to note. The collaboration brings together Abcam’s antibody characterisation expertise with EpiCypher’s CUTANA™ ChIC/CUT&RUN platform to co-develop and validate reagents for […]
Two new systems, Co-Scientist and Robin, use teams of AI agents to search literature, generate testable hypotheses and even analyse laboratory data. Early results, published in Nature, include drug repurposing candidates validated in cellular assays for leukaemia and eye disease.
BioMed X, a build-to-solve innovation engine for the pharmaceutical sector, has formally launched the BioMed X Innovation Circle, a new initiative designed to bring together leaders from across the life sciences ecosystem. The group was unveiled during the BIO International Convention 2026, held recently in the United States, and marks a further step in the […]
Korean scientists have identified a novel envelope protein from simian retrovirus 2 that outperforms the industry-standard RD114 protein for manufacturing CAR-T and CAR-NK cell therapies. The discovery, published in Nature Communications, boosted viral titres, gene transduction and tumour control in mice, offering a route to more efficient and affordable cancer immunotherapy production.
Dutch toxicology company Toxys has announced the publication of OECD Test Guideline 446A for ToxTracker, its stem cell-based genotoxicity testing platform, marking formal recognition of the assay within international regulatory testing frameworks. The guideline, issued through the OECD Test Guidelines Programme, opens the door to wider use of ToxTracker in chemical, pharmaceutical and consumer product […]
Researchers at Chiba University in Japan have achieved the first total synthesis of bousigonine B and a new synthesis of bisleuconothine A, two highly complex monoterpenoid indole alkaloids (MIAs) with demonstrated anticancer activity. Using an innovative organocatalytic cascade strategy and bioinspired coupling reactions, the team has established a versatile platform that may accelerate the development […]
PhoreMost Limited, the Cambridge-based oncology biotech, has announced its lead drug candidate, PMC-001, a next-generation small molecule microtubule targeting agent (MTA) designed to treat both primary and secondary brain cancers. The company is preparing regulatory filings ahead of first-in-human clinical trials.
ProBioGen, the Berlin-based contract development and manufacturing organisation (CDMO), has appointed Dr Simon Johannes Bulling, PhD, as Chief Operating Officer (COO). The appointment signals a strategic intensification of the company’s operational ambitions across biologics, viral vectors, vaccines, and cell and gene therapies.